Axon Clinical s.r.o.
- Address
- Ostrovskeho 253/3, Smichov, 150 00 Prague, Czechia
Axon Clinical s.r.o. - Advanced Ophthalmology, Neurology & Gastroenterology Research Center
Axon Clinical s.r.o. is a specialized clinical research center with extensive expertise in conducting multi-phase trials across diverse therapeutic areas. The center demonstrates particular strength in ophthalmological conditions, with a comprehensive focus on age-related macular degeneration and its variants, including geographic atrophy, neovascular AMD, and diabetic macular edema. Their ophthalmology portfolio encompasses innovative intravitreal therapies, complement inhibitors, and novel drug delivery systems.
- Geographic Atrophy and Age-Related Macular Degeneration: Multiple Phase 2/3 trials evaluating complement inhibitors, visual function preservation, and long-term safety extensions
- Neurological Disorders: Parkinson's disease motor fluctuation studies and migraine prevention/acute treatment trials, including novel CGRP antagonists and botulinum toxin therapies
- Inflammatory Bowel Disease: Comprehensive research in Crohn's disease and ulcerative colitis, featuring biologics, JAK inhibitors, and long-term maintenance studies
- Retinal Vascular Diseases: Advanced trials in diabetic macular edema and neovascular AMD with anti-VEGF agents and combination therapies
The center's research infrastructure supports complex trial designs including double-masked randomized controlled studies, open-label extensions, and dose-finding protocols. With experience spanning rare conditions such as SORD deficiency and thyroid eye disease, alongside high-prevalence diseases, Axon Clinical demonstrates versatility in managing diverse patient populations and sophisticated endpoint assessments including endoscopic evaluations, fundus autofluorescence imaging, and motor function diaries.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Janssen Cilag International3active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International6trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Axon Clinical s.r.o.
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 7 | Unknown | 2021-08-27 | 2026-06-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.